Senores Pharmaceuticals is a thought-leading pharmaceutical company all set to leave its footprints in the global market. They at Senores Pharmaceuticals are committed to innovate and manufacture products of highest international quality standards to cater to the increasing new-age demands of the global healthcare industry. Senores Pharmaceuticals is currently developing niche, complex and specialty pharmaceuticals products.

Senores Pharmaceuticals, an Book Built Issue amounting to ₹582.11 Crores, consisting an Fresh Issue of 127.87 Lakh Shares worth ₹500.00 Crores and an Offer for Sale of 21.00 Lakh Shares totalling to ₹82.11 Crores. The subscription period for the Senores Pharmaceuticals IPO opens on December 20, 2024, and closes on December 24, 2024. The allotment is expected to be finalized on or about Thursday, December 26, 2024, and the shares will be listed on the BSE & NSE with a tentative listing date set on or about Monday, December 30, 2024.

The Share price band of Senores Pharmaceuticals IPO is set at ₹372 to ₹391 per equity share. The Market Capitalisation of the Senores Pharmaceuticals Limited at IPO price of ₹391 per equity share will be ₹1,800.69 Crores. The lot size of the IPO is 38 shares. Retail investors are required to invest a minimum of ₹ 14,858, while the minimum investment for High-Net-Worth Individuals (HNIs) is 14 lots (532 shares), amounting to ₹ 208,012.

Equirus Capital Private Limited, Ambit Private Limited and Nuvama Wealth Management Limited are the book-running lead manager while Link Intime India Private Limited is the registrar for the Issue. 

Senores Pharmaceuticals Limited IPO GMP Today
The Grey Market Premium of Senores Pharmaceuticals Limited IPO is expected to be ₹176 based on the financial performance of the company. No real trading is done on the basis of Grey Market Premium that's why no real discovery of price can be done before the listing of shares on the stock exchange. The Grey Market Premium totally depends upon the Demand and Supply of the shares of the company in unorganized manner which is not recommended. The Grey Market Premium is mentioned for educational and informational purposes only.

Senores Pharmaceuticals Limited Day Wise IPO GMP Trend 

   

Date	IPO Price	Expected Listing Price	GMP	Last Updated
23 December 2024	₹ 391	₹567	₹ 176 (45.01%)	07:00 PM; 23 Dec 2024
22 December 2024	₹ 391	₹547	₹ 156 (39.95%)	07:00 PM; 22 Dec 2024
21 December 2024	₹ 391	₹547	₹ 156 (39.95%)	02:44 PM; 21 Dec 2024
19 December 2024	₹ 391	₹ 497	₹ 106 (27.15%)	05:00 PM; 19 Dec 2024

Senores Pharmaceuticals Limited IPO Live Subscription Status Today: Real-Time Updates
As of 07:00 on 24 December 2024, the Senores Pharmaceuticals IPO live subscription status shows that the IPO subscribed 93.69 times on its Final day of subscription period. Check the Senores Pharmaceuticals IPO Live Subscription Status Today at BSE.

Senores Pharmaceuticals IPO Anchor Investors Report
Senores Pharmaceuticals has raised ₹260.63 Crores from Anchor Investors at a price of ₹391 per shares in consultation of the Book Running Lead Managers. The company allocate 66,65,725 equity shares to the Anchor Investors. Check Full List of Senores Pharmaceuticals Anchor Investor List.

Note:- Equity Shares allotted to Anchor Investors (if any) are allotted from Qualified Institutional Buyers (QIBs) reservation portion.
Note:- The Number of shares offered shown IPO subscription section table is calculated at the lower end of the price band and Number of shares calculated in IPO details table section is calculated at upper end of the price band in case of Book Building Issue, so there can be difference. This is because we assume shares will be issued by the company at upper band as Anchor Investors also subscribe at upper band and shares will be issued at lower band only if in case of undersubscription of IPO.
Note:- Market Maker portion (if any) are not shown separately in subscription table and included in NIIs reservation portion

Senores Pharmaceuticals Limited IPO Allotment Date - Step by Step Guide to Check Allotment Status Online
Senores Pharmaceuticals IPO allotment date is 26 December, 2024, Thursday. Senores Pharmaceuticals IPO Allotment will be out on 26th December 2024 and will be live on Registrar Website from the allotment date. Check Senores Pharmaceuticals IPO Allotment Status here. Here's how you can check the allotment status:
- Navigate to the IPO allotment status page.
- Select Senores Pharmaceuticals Limited IPO from the dropdown list of IPOs.
- Enter your application number, PAN, or DP Client ID.
- Submit the details to check your allotment status.
By following either of these methods, investors can quickly determine their allotment status and proceed accordingly with their investments.

Objectives of Senores Pharmaceuticals Limited IPO
Senores Pharmaceuticals proposes to utilise the Net Proceeds towards the following objects: 
1. ₹1,070.00 Million is required for Investment in one of their Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in their Atlanta Facility;
2. ₹734.80 Million is required for Re-payment/pre-payment, in full or in part, of certain borrowings availed by their Company;
3. ₹202.20 Million is required for Investment in their Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiary;
4. ₹432.59 Million is required for Funding the working capital requirements of the Company;
5. ₹594.83 Million is required for Investment in our Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”) and Ratnatris Pharmaceutical Private Limited (“Ratnatris”) to fund their working capital requirements; and
6. Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.

Refer to Senores Pharmaceuticals Limited RHP for more details about the Company.

Check latest IPO Review & analysis, Live IPO GMP today, Live IPO Subscription Status Today, Share Price, Financial Information and other details before applying in the IPO.

The Upcoming IPOs in this week and coming weeks are Ventive Hospitality, Senores Pharmaceuticals, Carraro India, Solar91 Cleantech, Unimech Aerospace, Rosmerta Digital, Indo Farm, and Avanse Financial.

The Current active IPO is Transrail Lighting, Mamata Machinery, DAM Capital, Sanathan Textiles, Concord Enviro, Newmalayan Steel, Identical Brain Studios and NACDAC Infrastructure.

The Closed IPOs are   International Gemmological, Hamps Bio.

The Recently Listed IPOs which is available for trading in stock Market are Inventurus Knowledge, Yash Highvoltage, Jungle Camps, Toss The Coin, Dhanlaxmi Corp, Emerald Tyre Manufacturers, Nisus Finance, Ganesh Infraworld, Agarwal Toughened, Apex Ecotech, Rajputana Biodiesel, Rajesh Power Services, C2C Advanced System, Enviro Infra Engineers, Waaree Energies Limited IPO, Diffusion Engineers Limited IPO, KRN Heat Exchanger Limited IPO, P N Gadgil Jewellers Limited IPO, Bajaj Housing Finance Limited IPO, Gala Precision Engineering Limited IPO, Premier Energies Limited IPO, Orient Technologies Limited IPO, Interarch Building Products Limited IPO, Unicommerce eSolutions Limited IPO and many more.

Read more

About Senores Pharmaceuticals Limited

BUSINESS OVERVIEW
Senores Pharmaceuticals is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Their strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing us as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, they strategically identify commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets. They leverage their R&D capabilities to develop and manufacture a portfolio of differentiated complex pharmaceutical products. Their focus on quality and their ability to identify specialty and complex molecules has resulted in a pipeline of curated complex products spanning diverse dosage forms and therapeutic domains, demonstrated through their partnerships in the Regulated Markets of US, Canada and United Kingdom with foreign and Indian pharmaceutical companies including Prasco LLC, Lannett Company Inc., Jubilant Cadista Pharmaceuticals Inc., Alkem Laboratories Limited, Sun Pharmaceuticals Industries Limited, Dr. Reddy’s Laboratories Inc. and Cipla USA Inc. They have a presence in the Emerging Markets across 43 countries. They also manufacture critical care injectables and APIs.

The Bankers of the Company are HDFC Bank Limited and ICICI Bank Limited.

INDUSTRY ANALYSIS

Indian Pharmaceutical Market Overview
The Indian pharmaceutical market is among the fastest-growing in the world, witnessing a value increase from USD 19.0 billion in 2018 to USD 23.8 billion in 2023. The pharmaceutical market in India is dominated by generics, which account for around 96.2% of drug consumption in the country in terms of value. However, only about 10% of the drugs in the domestic market are unbranded/generic generics, marketed with just their chemical names as commodity generics.

Some of the growth drivers for rapid growth in the IPM include an increase in chronic patient population, insurance penetration, trade generics, demand from tier II and III cities, and government schemes focused on drug access.

Growth in Hospital Business Segment: In recent years, India has witnessed significant growth in hospitals and hospital beds. From a current bed density of 1.6 per 1000 people40, the country aims to achieve 2.0 per 1000 by 2030, translating into 3.0 million beds by 203041. While affordability and accessibility of the local population to healthcare services have resulted in an increased number of opted surgeries, medical tourism has also boosted the segment. For instance, medical tourists grew from 182,000 in 2020 to more than 500,000 in 202342. India is increasingly becoming a favored destination as medical travelers visiting India often save between 30% and 70% on treatments compared to those sought in developed nations. This has resulted in a rapidly growing critical care drug segment. According to IQVIA, the hospital channel market was estimated to be between USD 3.0-3.6 billion in 2018 and is projected to continue growing at a similar pace as the overall Indian Pharmaceutical Market (IPM). In 2023, the market is estimated to be USD 4.7-5.7 billion and is expected to reach USD 7.4-9.0 billion by 2028. Some of the key products sold through hospital channels as critical care drugs include anesthesia, antibiotics, pain management, and intrathecal therapies. The competition in the market is comparatively limited with some of the suppliers in India including Piramal Pharma, Senores Pharma, Aurobindo Pharmaceuticals, and Mankind Pharmaceuticals, to name a few.

With a growing number of surgical and medical procedures in hospitals, demand for critical drugs such as injectables has also increased. Additionally, globally, almost 64% of the new drug pipeline consists of injectables, indicating the growing significance of the segment and the next wave of opportunity for generic drug companies.

Oral solids have dominated the Indian pharma market, owing to ease of administration, patient comfort, flexibility in dosing, and ease of manufacturing- lower manufacturing costs translating to overall lower costs. Moreover, the market will continue to grow in the country, given the innovations in oral solid formulations ranging from modified release formats to orally disintegrating tablets, lipid-based formulations, coated particles, and multi-particulate systems, to name a few. Consequently, the oral solids segment is expected to grow at a CAGR of 9.7%, from USD 16.6 billion in 2023 to USD 26.3 billion by 2028.

At the same time, other formulations like injectables, inhalations, and liquids are also witnessing rapid growth. Injectables pegged at USD 3.3 billion in 2023 are expected to grow at a CAGR of 7.5% from 2023 to 2028 to reach USD 4.7 billion in 2028. The growth of the injectables market is fueled by technical and scientific advantages over other dosage forms. Injectable medications offer precise dosing, rapid onset of action, and enhanced bioavailability compared to oral formulations. They can also be formulated as long-acting or sustained-release formulations, improving patient compliance and convenience. Injectable drugs are more stable and compatible with complex molecules, making them ideal for targeted drug delivery and the administration of biologics. While injectables are preferred for fast-acting and precise dosing characteristics, topical formulations and inhalation products are preferred for their localized and disease-specific action. Oral liquids have also gained popularity in pediatric and geriatric formulations, while implants are also beginning to gain traction in the country. As a result, the "others" segment, including liquids, implants, sprays, inhalation products, etc., is expected to contribute the highest growth of 11.8% between 2023 and 2028.

Indian API Market Overview
The demand for pharmaceutical products corresponds directly to API sales, and as this demand grows, so does the need for APIs. As disease patterns shift from acute to chronic and translate into high drug volume consumption, the access to healthcare facilities and affordable medicine increases, along with an increase in the purchasing power of the middle class in the country; the growth of the API industry will follow suit. Moreover, with the increasing adoption of novel drugs, including biologics, coupled with the volume growth of the generics industry, the segment is expected to grow steadily. Notably, there is a rising preference for complex APIs like Highly Potent Active Pharmaceutical Ingredients (HPAPIs) or those derived from fermentation, contributing to improved drug efficacy and increasing production costs.

India is the third-largest producer of APIs, commanding an impressive 8% share of the Global API Industry. With over 500 distinct APIs manufactured within its borders, India emerges as a pivotal contributor, supplying 57% of APIs listed on the prequalified World Health Organization (WHO) roster.

The escalating tensions between Western nations and China have catalyzed a significant shift in the sourcing strategies of global pharmaceutical majors. Moreover, as China started following stringent environmental norms leading to production cuts during winters (approximately 40% of the factories in China were shut down to curb air pollution), followed by geopolitical changes, trade wars, and the COVID-19 pandemic, large companies and multi-national companies recognized the need to de-risk their supply chain. Increasingly, these companies are seeking alternative API providers outside China. India has swiftly risen to prominence as a compelling alternative source for bulk drugs, showcasing a remarkable trajectory of growth in this sector. Moreover, India has a distinctive advantage over its other Asian peers such as Bangladesh, Vietnam, and Indonesia, because of its infrastructure, large and skilled English-speaking population, large pool of scientists, competitive labor prices, and sophistication in information and communications technology. The early signs of adoption of this strategy in favor of India are already reflected in the Indian Ministry of Statistics and Programme Implementation’s Index of Industrial Production for the Manufacture of Pharmaceuticals, Medicinal Chemicals, and Botanical Products, which increased to 233.4 in FY24, up from 216.2 in FY23.

Additionally, the Indian API market particularly benefits from government policies promoting local production of APIs. From Production Linked Incentive (PLI) schemes, offering incentives ranging from INR 20 crore to INR 400 crore to bulk drug park development, the government's push for local formulation and API manufacturing is supporting the development of capabilities in complex areas such as fermentation, allowing the manufacturing of even broader portfolio of products and thus propelling the market on an accelerated growth path. This is also reflected in the growing number of FDA-approved API manufacturing sites in India, which has increased from 173 in 2018 to 209 in 2023.

BUSINESS STRENGTHS

1. Manufacturing for Regulated Market : Sensor Pharmaceuticals caters to the US, Canada, and UK markets through its US FDA-approved facility in Atlanta, USA. This facility has a strong compliance history, audited and approved four times by the US FDA, including in April 2024. It is also DEA-approved for controlled substances and meets the Trade Agreements Act and Buy American Act requirements, enabling government supplies.

2. Niche Product Portfolio for Regulated Market : The company focuses on developing complex, specialty products for small to mid-sized markets in the US, Canada, and UK. These niche products face lower competition, reduced price erosion, and ensure better profitability compared to generic drugs.

3. Long-Term Marketing Collaboration : Sensor has 5-7 year agreements with major pharmaceutical companies like Lannett, Prasco, Jubilant Cadista, and Sun Pharma. These partnerships involve in-licensing, product development, and distribution, supported by manufacturing at the Atlanta facility.

4. Presence in Emerging Market : Sensor operates in 43 emerging markets across Latin America, Africa, CIS, Southeast Asia, and the Middle East. It leverages its Chhatral Facility to launch patented complex products with minimal competition, focusing on value-added offerings for these regions.

5. Strong R&D Capabilitie : The company drives innovation through robust R&D in the US and India, identifying and developing high-growth, low-competition pharmaceutical products. Its expertise spans formulation development, bioequivalence studies, and product filing, culminating in manufacturing at the Atlanta facility.

6. Experienced Leadership Tea : Led by seasoned professionals like Promoters Swapnil Jatinbhai Shah (15+ years in pharma) and Ashokkumar Vijaysinh Barot (21+ years in pharma), the management team brings expertise across pharmaceuticals, accounting, law, and marketing, ensuring strategic growth in regulated and emerging markets.

BUSINESS STRATEGIES

1. Strengthening Market Presence in Regulated Market : Sensor Pharmaceuticals aims to expand its reach in North America, focusing on the US, which constitutes 43% of the global pharmaceutical market. With a projected market value of USD 1,010 billion by 2028, the company is leveraging growth opportunities in this dominant healthcare sector.

2. NDA Product Launches in the U : The company plans to enter the US New Drug Application (NDA) segment with generic drugs offering five years of exclusivity. Sensor has a combination product in development and continues to explore innovative molecules for NDA filings.

3. Expansion into New Market : Targeting growth in both Regulated and Emerging Markets, Sensor leverages rising healthcare investments, population growth, and infrastructure advancements to broaden its market footprint.

4. Strategic CMO/CDMO Alliance : Sensor collaborates with Contract Development and Manufacturing Organizations (CDMOs) to access new markets, enhance manufacturing capacity, and mitigate production risks, ensuring technological and operational efficiency.

5. Enhancing Backward Integratio : By manufacturing its own APIs through its integrated subsidiary RLPL, Sensor achieves cost efficiency, quality control, and supply chain reliability. This vertical integration strengthens its formulations business and improves market competitiveness.

6. Inorganic Growth Through Acquisition : Sensor pursues strategic acquisitions, including controlling stakes in Havix and RPPL, to enhance its technical capabilities, strengthen product infrastructure, and deepen its presence in existing and new markets.

BUSINESS RISK FACTORS

1. Dependence on the US Market : A significant portion of Sensor's revenue comes from the US market, making it vulnerable to competition, regulatory actions, pricing pressures, demand fluctuations, and global events like pandemics. Non-compliance with foreign laws and trade policies could lead to penalties and impact its reputation and financial health.

2. Reliance on CDMO and CMO Customer : Sensor's operations heavily depend on a limited number of CDMO and CMO clients across both Regulated and Emerging Markets. Any disruption in these partnerships may affect its revenue streams.

3. Dependence on Third-Party Supplier : The company relies on domestic and international suppliers for raw materials. Supply chain disruptions, price volatility, and regulatory changes could adversely impact production and operational efficiency.

4. Loss-Making Subsidiarie : Subsidiaries like RPPL and RLPL have incurred losses, requiring potential financial support from Sensor. Limited ability to sustain this support may strain the company’s resources and reputation.

5. Challenges in Market Expansio : Expanding into new markets exposes Sensor to cultural, economic, and regulatory challenges, including competition, compliance risks, supply chain dependencies, and geopolitical instability.

NOTE : Sensor Pharmaceuticals faces risks tied to its heavy reliance on the US market, a limited customer base, third-party suppliers, and loss-making subsidiaries. Additionally, its strategy to expand into new markets presents challenges that could impact growth and profitability. Effective mitigation strategies are crucial to sustain business resilience and global expansion.